Using Cost-Effectiveness Evidence to Inform Decisions as to which Health Services to Provide

被引:13
作者
Cairns, John [1 ]
机构
[1] London Sch Hyg & Trop Med, Hlth Serv Res & Policy, London, England
关键词
cost-effectiveness threshold; decision making; drug adoption; health technology assessment; QALYs;
D O I
10.1080/23288604.2015.1124172
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This article focuses on three challenges concerning the use of cost-effectiveness thresholds to inform decision making regarding which services a third-party payer will fund. First, how is the appropriate cost-effectiveness threshold or threshold range to be determined or, indeed, should there be a single threshold or multiple thresholds? Second, how can the valuation of health benefits be refined to better capture the value of treatments to patients and to the economy as a whole? Third, how is the tension between cost-effectiveness and the affordability and sustainability of health services to be managed? It concludes that whatever other factors are considered in addition to cost-effectiveness, and whether the decision-making process is more or less deliberative, cost-effectiveness thresholds are important. Though there is a range of sources for identifying appropriate thresholds, using the opportunity cost in terms of the health benefits from displaced activities will minimize the problem of cost-effective interventions not being affordable and will facilitate the efficient use of scarce resources. Finally, although experience using weighted quality-adjusted life years (QALYs) is currently very limited, it is likely to be an important area in the future.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 20 条
[11]   The NICE cost-effectiveness threshold - What it is and what that means [J].
McCabe, Christopher ;
Claxton, Karl ;
Culyer, Anthony J. .
PHARMACOECONOMICS, 2008, 26 (09) :733-744
[12]   End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes? [J].
McGuire, Alistair ;
Drummond, Michael ;
Martin, Monique ;
Justo, Nahila .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) :599-605
[13]   Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines [J].
Newall, A. T. ;
Jit, M. ;
Hutubessy, R. .
PHARMACOECONOMICS, 2014, 32 (06) :525-531
[14]  
Revill P, 2014, 98 CHE U YORK
[15]  
Ryen L, 2015, HEALTH ECON, V24, P1287
[16]  
Shah K., 2015, VALUING HLTH END LIF
[17]   Multiple Criteria Decision Analysis for Health Technology Assessment [J].
Thokala, Praueen ;
Duenas, Alejandra .
VALUE IN HEALTH, 2012, 15 (08) :1172-1181
[18]   Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall [J].
van de Wetering, E. J. ;
Stolk, E. A. ;
van Exel, N. J. A. ;
Brouwer, W. B. F. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (01) :107-115
[19]  
WHO, COST EFF THRESH
[20]  
Woods B, 2015, 109 CHE U YORK